Open AccessFirst-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study
Author(s) -
Mostafa El-Serafi,
Ahmed A. Zeeneldin,
Ibrahim M. Abdelsalam,
Hanan R. Nassar,
Manar M. Moneer,
Wafa H. Buhoush
Publication year - 2018
Publication title -
journal of egyptian national cancer institute/journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2018.01.002
Subject(s) - medicine , paclitaxel , metastatic breast cancer , oncology , cisplatin , breast cancer , cancer , chemotherapy
Breast cancer (BC) is the commonest cancer among females worldwide. Some patients present initially at advanced stages and more than 50% of them will develop metastasis (MBC) at some point. Compared to single agents, combination chemotherapy produces higher response rates (RR), longer progression-free survival (PFS) than single agents. This is associated with remarkably higher toxicities. At the same time, overall survival (OS) is comparable. This study aimed to compare safety and efficacy of combination and sequential chemotherapy.